Related Experiment Videos
[Treatment of coronary disease with elantan. Results of a multicenter study]
Insights
Elantan therapy effectively treated coronary heart disease (CHD) and angina pectoris. A 14-day treatment showed high cure rates, reducing attack frequency and nitrate use in CHD patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Coronary heart disease (CHD) affects millions globally, necessitating effective treatment options.
- Existing therapies for CHD and angina pectoris often have limitations, driving the search for improved interventions.
Purpose of the Study:
- To evaluate the efficacy and tolerance of a 14-day Elantan therapy in a large patient cohort under real-world conditions.
- To assess Elantan's impact on angina pectoris attack frequency and the need for acute nitrate medication.
Main Methods:
- A multicenter study involving 10,229 patients diagnosed with coronary heart disease.
- Patients received Elantan 20 at a dosage of 3 tablets daily for 14 days.
- Outcomes were measured by cure rate, remission of angina pectoris, and reduction in nitrate consumption.
Main Results:
- A cure rate of 79.9% was observed in patients with pre-existing CHD, with 50% achieving complete remission of angina pectoris attacks.
- An additional 29.9% experienced a reduced frequency of attacks, correlating with decreased use of acute nitrates.
- In treatment-naïve patients, Elantan therapy demonstrated a high cure rate of 91%.
Conclusions:
- Elantan therapy is effective and well-tolerated for managing coronary heart disease and angina pectoris in a large, diverse patient population.
- The study supports Elantan as a valuable therapeutic option for both previously treated and newly diagnosed patients with angina pectoris.
Abstract:
10,229 patients with coronary heart disease (CHD) took part in a multicenter study to verify the efficacy and tolerance of a 14 days lasting therapy with elantan under practical conditions. The majority of patients with an average age of 59 +/- 10 years (58.8% men, 40.3% women) had suffered about four years on CHD and had already been treated with coronary efficient drugs. The 14-day therapy with elantan 20 in a dosage of 3 X 1 tabl./day showed a cure rate of 79.9% in patients who had already been treated, a complete remission of the angina pectoris attacks being achieved in 50% and a reduction of the frequency of the attacks in a further 29.9%. The reduced frequency of the attacks was associated with a reduced consumption of acute nitrates (nitroglycerine capsules). With the smaller group of patients who were being treated for angina pectoris for the first time, the therapy with elantan was characterized by a cure rate of 91%.